Baudax Bio, Inc. (BXRX)
$0.3103
-0.04 (-11.34%)
Rating:
Recommendation:
-
| Symbol | BXRX |
|---|---|
| Price | $0.3103 |
| Beta | 2.055 |
| Volume Avg. | 3.03M |
| Market Cap | 2.848M |
| Shares () | - |
| 52 Week Range | 0.3-12.24 |
| 1y Target Est | - |
| DCF Unlevered | BXRX DCF -> | |
|---|---|---|
| DCF Levered | BXRX LDCF -> | |
| ROE | 359.40% | Strong Buy |
| ROA | -260.39% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -82.13% | |
| P/E | - | |
| P/B | -0.14 | Neutral |
Latest BXRX news
About
Download (Excel)Dr. Geraldine A. Henwood Ph.D.
Healthcare
Biotechnology
NASDAQ Capital Market
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.